Author
@BiopharmIQ BiopharmIQ
Institutional-grade biotech catalyst and hedge-fund 13F data feed
Publishes a high-volume biotech intelligence feed: clinical/
trader score
·
hit rate
·
mean α
·
signals 14d
241
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Not yet in the scored-bets universe (fewer than 20 scoreable calls). Their last-14d mentions, direction-adjusted, have moved -3.0% since posting (mean over 104 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-16 | RHHBY | @BiopharmIQ | +0.00 | The author explains why FDA approval odds and estimated stock-move size should be evaluated together. | +7.1% | tweet ↗ |
| 2026-10-16 | RHHBY | @BiopharmIQ | +0.10 | The post compares an earlier FDA probability and move forecast with today's approval and 0.58% gain. | +7.1% | tweet ↗ |
| 2026-10-16 | RHHBY | @BiopharmIQ | +0.00 | The author explains why FDA approval odds and estimated stock-move size should be evaluated together. | +7.1% | tweet ↗ |
| 2026-10-16 | RHHBY | @BiopharmIQ | +0.50 | The FDA approved Enspryng as the first at-home subcutaneous treatment for thyroid eye disease. | +7.1% | tweet ↗ |
| 2026-10-16 | GSK | @BiopharmIQ | +0.00 | The tweet lists upcoming October FDA decision dates for three companies. | +2.5% | tweet ↗ |
| 2026-10-16 | INO | @BiopharmIQ | +0.00 | The tweet lists upcoming October FDA decision dates for three companies. | -9.4% | tweet ↗ |
| 2026-10-16 | VTRS | @BiopharmIQ | +0.00 | The tweet lists upcoming October FDA decision dates for three companies. | · | tweet ↗ |
| 2026-10-16 | RHHBY | @BiopharmIQ | +0.50 | Enspryng received FDA approval for thyroid eye disease, with another decision expected in January 2027. | +7.1% | tweet ↗ |
| 2026-10-16 | REGN | @BiopharmIQ | +0.10 | The post summarizes opening biotech moves and their company-specific catalysts. | +1.8% | tweet ↗ |
| 2026-10-16 | TLSA | @BiopharmIQ | +0.00 | The post summarizes opening biotech moves and their company-specific catalysts. | · | tweet ↗ |
| 2026-10-16 | RHHBY | @BiopharmIQ | +0.20 | The post summarizes opening biotech moves and their company-specific catalysts. | +7.1% | tweet ↗ |
| 2026-10-16 | ATNM | @BiopharmIQ | +0.10 | The post summarizes opening biotech moves and their company-specific catalysts. | · | tweet ↗ |
| 2026-10-16 | TNGX | @BiopharmIQ | +0.00 | The post summarizes opening biotech moves and their company-specific catalysts. | +5.9% | tweet ↗ |
| 2026-10-16 | NBIX | @BiopharmIQ | +0.00 | The post summarizes opening biotech moves and their company-specific catalysts. | +5.2% | tweet ↗ |
| 2026-10-15 | DRMA | @BiopharmIQ | +0.50 | DRMA opened up 33% after a cosmetic-study update, with further Q4 readouts highlighted. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.